Suven Life Sciences LimitedQ1 FY27 Results & Financial Update
Suven Life Sciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹3.57 Cr, PAT ₹-127.61 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Suven Life Sciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Suven Life Sciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Suven Life Sciences reported revenue from operations of INR 3.5658 crore (Rs. 356.58 lakhs) for the quarter ended June 30, 2026, alongside other income of INR 7.5236 crore, bringing total income to INR 11.0894 crore.
The consolidated net loss for Q1 FY27 widened significantly to INR 127.6103 crore (Rs. 12,761.03 lakhs), resulting in a basic and diluted earnings per share (EPS) of INR -4.84.
The sharp expansion in net loss was driven by a substantial escalation in research and development expenses, which stood at INR 123.8310 crore for the quarter as clinical trial activities across global pipelines intensified.
Employee benefits expense for the period was recorded at INR 7.2818 crore, which includes INR 145.54 lakhs recognized as employee benefit expense in accordance with Ind AS 102 for stock options granted under the SLSL Employee Stock Option Scheme 2020.
Depreciation and amortisation expenses amounted to INR 2.1551 crore, while finance costs rose to INR 0.4761 crore during the quarter.
The company's clinical development portfolio recorded notable operational milestones during the period, including progress in late-stage Phase 3 trials for lead neuroscience candidates.
Profit after tax was ₹-127.61 Cr for the reported quarter. EPS was ₹-4.84 for the reported quarter.
01 · Business model
What does Suven Life Sciences do?
Suven Life Sciences Limited is a biopharmaceutical company engaged in drug discovery and the development of New Chemical Entities (NCEs) targeting central nervous system (CNS) disorders with high unmet medical needs globally.
The company operates on a consolidated basis with its wholly owned Delaware subsidiary, Suven Neurosciences, Inc., which handles clinical development programs in international markets.
Suven's principal business activity is structured around research and development in neuroscience, focusing on proprietary pipeline assets aimed at conditions such as Alzheimer's disease, narcolepsy, major depressive disorder, and other psychiatric disorders.
02 · Historical context
What shaped the business before this quarter
The company previously implemented the SLSL Employee Stock Option Scheme 2020 to align key employee incentives with long-term research goals.
In May and June 2025, shareholders approved a preferential issue of 6,40,02,999 convertible warrants at an exercise price of INR 134 per share.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹3.57 Cr |
| Total income | ₹11.09 Cr |
| Profit before tax | ₹-127.61 Cr |
| Profit after tax | ₹-127.61 Cr |
| EPS | ₹-4.84 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -3,578.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -3,578.7% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹7.52 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations for Q1 FY27 stood at INR 3.5658 crore, reflecting niche commercial inflows relative to ongoing clinical-stage operations.
Other income added INR 7.5236 crore to the total quarterly income of INR 11.0894 crore.
What drove margins
Research and development expenditure surged to INR 123.8310 crore for the quarter, forming the primary driver of the operating loss.
Employee benefits expenses reached INR 7.2818 crore (including ESOP charges), and finance costs were reported at INR 0.4761 crore.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in only one business segment, namely Research & Development, and does not report separate operating segments under Ind AS 108.
06 · Strategy & new businesses
How the company is trying to change its growth mix
During Q1 FY27, the Nomination & Remuneration Committee granted 1,33,200 stock options on May 13, 2026, and allotted 2,71,970 equity shares pursuant to employee option exercises.
07 · Reported developments
What changed operationally
Masupirdine (SUVN-502) achieved a 95% patient enrolment milestone in its global Phase 3 trial for agitation in Alzheimer's dementia.
A global Phase 3 clinical trial for Samelisant (SUVN-G3031) was initiated in April 2026 for treating excessive daytime sleepiness (EDS) in narcolepsy.
Ropanicant (SUVN-911) successfully completed its Phase 2b clinical trial evaluating efficacy and safety in Major Depressive Disorder (MDD).
08 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
As of June 30, 2026, the company received the entire preferential issue amount of INR 85,764.02 lakhs, of which INR 9,331.49 lakhs was received during Q1 FY27 for 1,85,70,133 warrants pending allotment.
Out of the total preferential issue proceeds of INR 85,764.02 lakhs, INR 40,950.29 lakhs had been utilised as of June 30, 2026, leaving an unutilised balance of INR 44,813.73 lakhs.
09 · Beyond the numbers
What changed beyond the numbers
Reported update
Pipeline advancement
SUVN-D4010 (Usmarapride) is finalizing its Phase 2 proof-of-concept study design for cognitive impairment in psychiatric disorders, and SUVN-I6107 completed its Phase 1 safety and pharmacokinetics study in preparation for Phase 2.
10 · Key Q&A
The quarter, answered directly
What does Suven Life Sciences do?
Suven Life Sciences Limited is a biopharmaceutical company engaged in drug discovery and the development of New Chemical Entities (NCEs) targeting central nervous system (CNS) disorders with high unmet medical needs globally.
What is the clearest takeaway from Q1 FY27?
Suven Life Sciences reported revenue from operations of INR 3.5658 crore (Rs. 356.58 lakhs) for the quarter ended June 30, 2026, alongside other income of INR 7.5236 crore, bringing total income to INR 11.0894 crore.
What drove revenue or demand?
Revenue from operations for Q1 FY27 stood at INR 3.5658 crore, reflecting niche commercial inflows relative to ongoing clinical-stage operations.
What mattered most for margins or profitability?
Research and development expenditure surged to INR 123.8310 crore for the quarter, forming the primary driver of the operating loss.
What changed operationally beyond the headline numbers?
During Q1 FY27, the Nomination & Remuneration Committee granted 1,33,200 stock options on May 13, 2026, and allotted 2,71,970 equity shares pursuant to employee option exercises.
What should the next disclosure help confirm?
Completion of patient enrolment for SUVN-502 projected by the end of September 2026, with the last patient last visit expected in Q1 calendar year 2027 ahead of database lock and result reporting in Q2 calendar year 2027.
11 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
12 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
SUVN-502 trial completion: Completion of patient enrolment for SUVN-502 projected by the end of September 2026, with the last patient last visit expected in Q1 calendar year 2027 ahead of database lock and result reporting in Q2 calendar year 2027.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.